ArticleZeitschrift fur Rheumatologie2009
[Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
Article in Zeitschrift fur Rheumatologie, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Systemic Therapy of Psoriasis in Children-Proposal of an Algorithm for Interdisciplinary Teamwork.Journal of clinical medicine · 2024Article
- Article
- [Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment].Zeitschrift fur Rheumatologie · 2018Article
- [Role of orthopedic rheumatologist in the therapy of rheumatic diseases with biologics].Der Orthopade · 2014Article
- [Are the recommendations on tuberculosis screening still valid? Interferon gamma release assay (IGRA) and/or tuberculin skin test for diagnosis of latent tuberculosis infection (LTBI)].Zeitschrift fur Rheumatologie · 2013Article
- [Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].Zeitschrift fur Rheumatologie · 2013Article
- [Screening investigations during intensified immunosuppression in children and adolescents. Part 1].Zeitschrift fur Rheumatologie · 2013Review
- [Intracerebral lesions after TNF-alpha inhibitor therapy with pre-existing sarcoidosis and sacroiliitis].Zeitschrift fur Rheumatologie · 2012Article
- [Clinical presentation of tuberculosis in routine practice].Zeitschrift fur Rheumatologie · 2012Article
- [Modern therapy of psoriasis : evidence-based, patient-centered, goal-oriented].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2012Article
- [Biologicals 2012].Der Orthopade · 2012Article
- [A decade of biologics in dermatology].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2012Review
- [Tuberculosis : diagnostics and prophylaxis].Zeitschrift fur Rheumatologie · 2011Article
- [Infectious complications of biologic therapy in patients with rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2010Review
- [Food and Drug Administration extends malignancy warning for TNF-alpha inhibitors].Zeitschrift fur Rheumatologie · 2009Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the increased risk of tuberculosis (TB) under treatment with TNF-alpha inhibitors for rheumatoid arthritis and other autoimmune diseases, precautionary measures are required before initiating TNF-alpha-inhibitor therapy. Patients should have active TB ruled out and screening for latent TB infection should be performed. The screening should include chest X-ray, complete medical history, and the administration of a highly specific interferon-gamma-release assay (IGRA). (In the future, the reimbursement of IGRA tests under an analogue procedure code is expected to be formalized by the application of a code specific to the TB-IGRA procedure.) As tuberculin skin test (TST) results can be expected to be either false-positive or false-negative in these patients, the TST, as commonly performed in the past, is recommended only in exceptional situations. For chemopreventive treatment of latent TB infection (LTBI), isoniazid is usually given for 9 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.